Amgen (AMGN) fundamentals: P/E, valuation, undervalued?
Amgen · Health Care · ref. ETF XLV · price $412.84
In short — Amgen trades at 25.9× earnings (P/E), 16.9× forward, with a net margin of 23.0 % and revenue growth of +10 %. Read: Cheap for the growth (P/E 17 for ~65% growth (PEG 0.3)).
Is Amgen stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$412.84+40.5% over range
Oct 14, 25low $291.16 · high $444.12Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
36% recommend buying · 22 analysts
Valuation : Cheap for the growth — P/E 17 for ~65% growth (PEG 0.3)
Valuation
25.9
P/E (price/earnings)
16.9
Forward P/E
0.40
PEG
19.1
Price/book (P/B)
$223.2B
Market cap
15.92
EPS
Profitability & growth
23.0 %
Net margin
+10 %
Revenue growth
+65 %
Earnings growth
$57.3B
Total debt
Amgen income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $26.3B | $6.6B | 24.9 % |
| 2023 | $28.2B | $6.7B | 23.8 % |
| 2024 | $33.4B | $4.1B | 12.2 % |
| 2025 | $36.8B | $7.7B | 21.0 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Amgen's P/E and is the stock undervalued? What's a good P/E?
Amgen's P/E is 25.9 (forward 16.9). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Amgen profitable?
Amgen has a net margin of 23.0 % (EPS 15.92). The company is profitable.
Is AMGN stock expensive?
Our read: "Cheap for the growth" — P/E 17 for ~65% growth (PEG 0.3). Cross-check with growth and sector.
💬 A question about Amgen? The JPI assistant answers using our backtest data.